Silence Therapeutics is making significant strides in ASCVD treatment with promising RNAi therapeutics. Their recent PV data highlights marked improvements in patient outcomes and supports the potential for widespread clinical application.
Keros Therapeutics revealed promising clinical data on its Elritercept (KER-050) program for treating hematological disorders at the 29th Annual Hybrid Congress of the European Hematology Association. The trials showed significant strides in addressing myelodysplastic syndromes and myelofibrosis, with encouraging outcomes in transfusion independence and patient-reported fatigue improvements.
The article discusses the controversy surrounding the Alzheimer's drug Leqembi, highlighting its severe side effects masked by a benign acronym, leading to fatalities such as that of Genevieve Lane. It stresses the need for improved patient education and regulatory scrutiny.
